Frequent
OCS Use
Serious
Exacerbations
Impaired
Lung Function
Poor Symptom
Control
Frequent
OCS Use
Serious
Exacerbations
Impaired
Lung Function
Poor Symptom
Control
Blood EOS
≥150 cells/μL
FeNO ≥20 ppb
Sputum EOS ≥2%
Clinically
allergen-driven‡
Blood EOS
≥150 cells/μL
FeNO ≥20 ppb
Sputum EOS ≥2%
Clinically
allergen-driven‡
By clicking "Home" your progress will be lost.
© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All rights reserved. MAT-US-2205077 v8.0 - P Exp Date: 09/11/2026